Free tool
FAERS Monitor: Botox Cosmetic
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming BLA 103000 or its brand name (Botox Cosmetic, Onabotulinumtoxina). Reports on generic versions are filed under their own applications.
Reports
77,970
Serious
15,443
20% of reports
Hospitalization
4,780
Death reported
2,225
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- drug ineffective26,774
- off label use11,721
- therapeutic response decreased4,513
- headache4,135
- product preparation error3,646
- injection site pain3,468
- eyelid ptosis3,149
- multiple use of single-use product2,866
- migraine2,406
- nausea2,245
- pain1,921
- fatigue1,878
- muscular weakness1,820
- dizziness1,813
- dysphagia1,731
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2004 | 102 |
| 2005 | 102 |
| 2006 | 110 |
| 2007 | 146 |
| 2008 | 454 |
| 2009 | 341 |
| 2010 | 4,860 |
| 2011 | 1,455 |
| 2012 | 2,710 |
| 2013 | 3,065 |
| 2014 | 3,096 |
| 2015 | 3,398 |
| 2016 | 4,998 |
| 2017 | 4,233 |
| 2018 | 4,692 |
| 2019 | 6,167 |
| 2020 | 5,224 |
| 2021 | 5,623 |
| 2022 | 5,185 |
| 2023 | 7,533 |
| 2024 | 5,357 |
| 2025 | 5,319 |
| 2026 | 3,800 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 20,976,189 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| multiple use of single-use productSignal | 2,866 | 280.0 | 265.8 | 390,365 |
| eyelid ptosisSignal | 3,149 | 120.6 | 115.7 | 257,975 |
| product preparation errorSignal | 3,646 | 58.0 | 56.0 | 168,063 |
| therapeutic response decreasedSignal | 4,513 | 21.6 | 21.0 | 82,340 |
| migraineSignal | 2,406 | 6.9 | 6.7 | 11,993 |
| drug ineffectiveSignal | 26,774 | 5.6 | 5.5 | 105,004 |
| dysphagiaSignal | 1,731 | 5.0 | 4.8 | 5,445 |
| muscular weaknessSignal | 1,820 | 4.4 | 4.2 | 4,682 |
| off label useSignal | 11,721 | 3.6 | 3.6 | 23,172 |
| injection site painSignal | 3,468 | 3.1 | 3.0 | 4,865 |
| headache | 4,135 | 1.8 | 1.7 | 1,459 |
| dizziness | 1,813 | 1.0 | 0.9 | 1 |
| pain | 1,921 | 0.8 | 0.8 | 57 |
| nausea | 2,245 | 0.8 | 0.7 | 168 |
| fatigue | 1,878 | 0.6 | 0.6 | 367 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.